UGT2B15 Y85D - GET-Evidence

Note: This variant has not been sufficiently evaluated by a GET-Evidence editor.

To be considered sufficiently evaluated a variant must have both "variant evidence" and "clinical importance" scores filled in.

Please help improve GET-Evidence by evaluating evidence for this variant!


(See the latest version)

UGT2B15 Y85D

(UGT2B15 Tyr85Asp)

You are viewing an old version of this page that was saved on December 5, 2010 at 6:43pm by Genome Importing Robot.

Short summary


Variant evidence
Computational -
Functional -
Case/Control -
Familial -
Clinical importance
Severity -
Treatability -
Penetrance -


Insufficiently evaluated pharmacogenetic

(The "insufficiently evaluated" qualifier is assigned automatically based on the above evidence and importance scores.)

Inheritance pattern


Summary of published research, and additional commentary


Allele frequency

  • C @ chr4:69536084: 50.8% (5458/10746) in EVS
  • C @ chr4:69218678: 50.0% (40/80) in GET-Evidence
  • Frequency shown in summary reports: 50.8% (5458/10746)


Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, Jang IJ, Shin SG. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94. PubMed PMID: 15961980.



Added in this revision:

hu04FD18 - CGI sample GS00253-DNA_F01_200_37
hom C @ chr4:69536084


hu43860C - CGI sample GS00253-DNA_A01_200_37
hom C @ chr4:69536084


Other external references

  • rs1902023
  • [lorazepam]
    N=24 Korean; PK: UGT2B15*2/*2 group vs UGT215*1/*1 showed 0.58 lower systemic clearance of lorazepam; p less than 0.001

Other in silico analyses

  • NBLOSUM100 score = 7
  • GET-Evidence autoscore = 1

Edit history

Gene search

"GENE" or "GENE A123C":

Log in